Ioxilan

• Description:

  Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs[1][2][3].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Biochemical Assay Reagents

• Type:

  Reference compound

• Related Pathways:

  Others

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/ioxilan.html

• Purity:

  98.34

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (C1=C (I) C (N (C (C) =O) CC (O) CO) =C (I) C (C (NCCO) =O) =C1I) NCC (O) CO

• Molecular Formula:

  C18H24I3N3O8

• Molecular Weight:

  791.11

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Cheng KT. Ioxilan carbonate particles. National Center for Biotechnology Information (US) ; 2004-2013. 2007 Sep 1.|[2]Chow SL, et al. Effect of iodixanol and ioxilan on QT interval and renal function in patients with systolic heart failure. Int J Cardiol. 2012 Jan 12;154 (1) :17-21.|[3] Nonionic Contrast Agents.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  107793-72-6